Alembic Pharma gets USFDA nod for Prucalopride tablets
Alembic Pharma gets USFDA nod for Prucalopride tablets — Alembic Pharmaceuticals has received final USFDA approval for Prucalopride Tablets, 1 mg and 2 mg. This approval enables the company to launch the drug in the US market. Prucalopride is used for the treatment of chronic idiopathic constipation. The product is a blockbuster drug with significant market potential in the US.
📊 STOCKS: APLLLTD | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Next articlespml infra publishes mandatory newspaper notice